Iovance Biotherapeutics, Inc.
No trades
Fundamentals and stats
EPS and revenue snapshot
In the last quarter, the company reported −0.18 USD per share, beating the −0.17 USD estimate by −2.90%. Revenue for the same period reached 86.71 M USD, despite the estimate of 80.71 M USD. For the next quarter, analysts expect −0.14 USD in earnings per share and 82.55 M USD in revenue.
Next report date—
Report period—
EPS estimate—
Revenue estimate—
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise